Member Info for hants

This placing is excellent and a great way to reduce dilution. Instead of future shares being issued at a cheap conversion price, shares are being issued today at a higher price to pay down the loan This means that fewer shares need to be issued in order to achieve the same amount of cash.

Sensible analysis, thank you.

When the Hanta LFT launches, I'll treat everybody to dinner at the Whetherby Whaler.

You okay?

Honestly, on the day a director has just reported a significant buy, I don't think you should be worrying about sells by random people who have no more information than us, which may or may not be sells anyway.

You sure about that squire?

He's busy pumping over on #mka too.

I'm going to stick my neck on the line here, and predict that a tiny bit below 40p is the lowest this will go. I'm also going to stick my neck out even further and predict that #mka will never be this price again. Bold words perhaps, but lets see. I've bought more at 41p. May not be the absolute bottom, but happy with that. I anticipate a strong reversal.

Looks like it's trying to fill the gaps on the chart, good chance it will go as low as 38p. I'll be surprised if it goes below that. Traders doing their thing. Those keen on getting in or buying more, will be taking the opportunity.

Nothing material that I'm aware of. If you're not buying or selling, come back another day. This is pretty much the bottom, most likely I think!

I find it truly amazing there's any sellers at the price. I mean, why would you buy shares, hold them, and sell them just as all the exciting stuff is just about to happen. And with the company's current market cap, we would need a real black swan event for the share price to go any lower.

Hmm, my post from yesterday did not age well.

24 to 29 Sep

Not that I'm trading this, it's half my portfolio and I'm just holding, but, they are there!

From this level, the R/T completetion represents a more than doubling of ROQs market cap from where it is today (ROQ's interest in the new, enlarged share capital). So, there's over 100% upside just on that alone, and today's RNS at a basic level tells us that nothing notable has changed and the deal is proceeding.

In addition to the above, we have the Lyramid carve out, on which we expect to hear very shortly - worth another $10 million in shares and maybe some cash.

Even if Lyramid didn't proceed, I see us in the 4s. With both, I see us in the 5s. Of course, that's only where the share price for ROQ was a few months ago, when none of this was even happening - so argueably the absolutely base case.

And, we don't have long to wait.

I've bought another 80,000 shares this morning, even though that bumps my average up by a fraction of a penny.

Quick summary of the RNS and my thoughts - not that I have a detailed understand of reverse takeovers.

£300,000 of funding, with £200k from advance subscriptions and 100k by way of a loan from A2A.

The subscriptions offer shares at a 20% discount to the next placing price, with a one-for-one warrant (exercisable for two years) for investors holding until 30 June 2026, incentivising retention over immediate flipping on for a quick profit.

The A2A loan has 5% interest, repayable within 12 months or upon deal completion, and convertible at 2p per share. (We're expecting to hear further on the R/T by very beginning of next year, so this is very much in line with what we have already been told).

Chairman Stephen West invested £45,000.

My own thoughts on this are:

Firstly, there will be one, if not two placings coming, within the next year or two, but the investors are probably already lined up for this. Previous RNS said "A2A Pharmaceuticals and its investors are committed to providing the majority of the funding requirement over the next two years with an investment of £6 million", and this £200,000 now is from "certain strategic investors." Therefore, I think we can assume there are likely to be some of the same people, and there will be a future share placing that is offered either solely or at least in the first instance, to this group, who are already existing investors. This is broadly positive, I feel.

The loan puts a a bit of a base in around the current level of 2p per share, so I'll be surprised if we go siginifantly below this level again. I see us only at or above this level, now.

The chairman putting in £45,000 is of course very positive, I'm sure that goes without saying! He also bought £36,0000 of shares earlier this year.

Whats going on here then!

CTAI put out an RNS pretty regularly, so I don't think we'll have long to wait for the next one, especially with Alludium launch so close.

Asimpleinvestor, you are absolutely correct, but the reality, rightly or wrongly, is that people do.

Not good.

The problem is with stuff like this, is that announcing it by RNS builds expectation which then comes to nothing, and creates negative sentiment. People then expect that same pattern to repeat next time, and you might therefore get a selloff in advance.

If they just dropped that interview on X out of the blue, as a nice surprise, without building it up in advance with an RNS, it would probably have been really well received.

And beyond that, CTAI is well positioned as we move towards a world of digital ID - (something I'm against, but, it's certainly happening!)

Two of the biggest movements at the moment are AI, and then in the UK, digital ID. CTAI can hopefully deliver on both these fronts.

Thanks Victoria, but this isn't the UKOG board.